Urine N-telopeptide excretion in dogs with appendicular osteosarcoma

Journal of Veterinary Internal Medicine

Volumn 20, Issue 2, 2006, Pages 335-341

  Lacoste, Hugues ^a   Fan, Timothy M ^a   De Lorimier, Louis Philippe ^a   Charney, Sarah C ^a  

^a Veterinary Teaching Hospital   (United States)

Author keywords

Bone resorption; Cancer pain; Canine; Malignant osteolysis; Pamidronate; Surrogate markers

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; TUMOR MARKER;

AMPUTATION; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CASE CONTROL STUDY; DOG; DOG DISEASE; FEMALE; MALE; METABOLISM; OSTEOSARCOMA; URINE;

ALKALINE PHOSPHATASE; AMPUTATION; ANIMALS; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE I; DOG DISEASES; DOGS; FEMALE; MALE; OSTEOSARCOMA; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; CANIS FAMILIARIS;

EID: 33645561290     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[335:UNEIDW]2.0.CO;2     Document Type: Article

References (41)

1. Chun R, de Lorimier LP. Update on the biology and management of canine osteosarcoma. Vet Clin North Am Small Anim Pract 2003;33:491-516.
2. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003;97(3 Suppl):866-873.
3. Clohisy DR, Ogilvie CM, Ramnaraine ML. Tumor osteolysis in osteopetrotic mice. J Orthop Res 1995;13:892-897.
4. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-10897.
5. Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer 2003;97(3 Suppl):874-879.
6. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clin Orthop Relat Res 2003;415(Suppl): S138-S147.
7. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88(12 Suppl):2919-2926.
8. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-2026.
9. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-856.
10. Hanson DA, Weis MAE, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptide in urine. J Bone Miner Res 1992;7:1251-1258.
11. Allen MJ. Biochemical markers of bone metabolism in animals: Uses and limitations. Vet Clin Pathol 2003;32:101-113.
12. Worsfold M, Powell DE, Jones TJW, et al. Assessment of urinary bone markers for monitoring treatment of osteoporosis. Clin Chem 2004;50:2263-2270.
13. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.
14. Barger A, Graca R, Bailey K, et al. Use of alkaline phosphatase staining to differentiate canine osteosarcoma from other vimentin-positive tumors. Vet Pathol 2005;42:161-165.
15. Allen MJ, Allen LCV, Hoffmann WE, et al. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000;69:123-127.
16. Ladlow JF, Hoffmann WE, Breur GJ, et al. Biological variability in serum and urinary indices of bone formation and resorption in dogs. Calcif Tissue Int 2002;70:186-193.
17. Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 1998;213:1002-1006.
18. Sanecki RK, Hoffmann WE, Hansen R, et al. Quantification of bone alkaline phosphatase in canine serum. Vet Clin Pathol 1993;22:17-23.
19. Sanecki RK, Hoffmann WE, Dorner JL, et al. Purification and comparison of corticosteroid-induced and intestinal isoenzymes of alkaline phosphatase in dogs. Am J Vet Res 1990;51:1964-1968.
20. Garzotto CK, Berg J, Hoffmann WE, et al. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000;14:587-592.
21. Wiklund T, Blomqvist C, Risteli L, et al. Type I and type III collagen metabolites in adult osteosarcoma patients. Br J Cancer 1996;73:106-109.
22. Behrens P, Bruns J, Ullrich KP, et al. Pyridinoline cross-links as markers for primary and secondary bone tumors. Scand J Clin Lab Invest 2003;63:37-44.
23. Ferrari S, Zolezzi C, Pratelli L, et al. Urinary excretion of pyridinium cross-links and serum osteocalcin levels in patients with primary high-grade osteosarcoma. Calcif Tissue Int 2003;73:1-4.
24. Açil Y, Springer I, Behrens P, et al. Differential enhancement of collagen crosslink excretion in cases of osteosarcoma and chondrosarcoma. J Cancer Res Clin Oncol 2003;129:583-588.
25. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
26. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358-1365.
27. Grynpas MD, Kasra M, Renlund R, et al. The effect of pamidronate in a new model of immobilization in the dog. Bone 1995;17(4 Suppl):225S-232S.
28. Sivagurunathan S, Muir MM, Brennan TC, et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 2005;20(3):390-398.
29. Takada T, Yoshinari N, Sugiishi S, et al. Effect of restraint stress on the progression of experimental periodontitis in rats. J Periodontol 2004;75:306-315.
30. Arai M, Nagasawa T, Koshihara Y, Yamamoto S, et al. Effect of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta 2003;1640:137-142.
31. Breur GJ, Allen MJ, Carlson SJ, et al. Markers of bone metabolism in dog breeds of different size. Res Vet Sci 2004;76:53-55.
32. DeLaurier A, Jackson B, Pfeiffer D, et al. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats. Res Vet Sci 2004;77:29-39.
33. Costa L, Demers LM, Speicher T, et al. Biochemical markers of bone turnover correlate with the extent of metastatic bone disease. American Society of Clinical Oncology Annual Meeting; May 1999.
34. Lipton A, Costa L, Ali SM, et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001;27:181-185.
35. Davis GJ, Kapatkin AS, Craig LE, et al. Comparison of radiography, computed tomography, and magnetic resonance imaging for evaluation of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 2002;220:1171-1176.
36. Wallack ST, Wisner ER, Werner JA, et al. Accuracy of magnetic resonance imaging for estimating intramedullary osteosarcoma extent in pre-operative planning of canine limb-salvage procedures. Vet Radiol Ultrasound 2002;43:432-441.
37. Lauten SD, Cox NR, Brawner WR Jr, et al. Use of dual energy x-ray absorptiometry for noninvasive body composition measurements in clinically normal dogs. Am J Vet Res 2001;62:1295-1301.
38. Berruti A, Dogliotti L, Osella G, et al. Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. Oncol Rep 2000;7:777-781.
39. Bachrach LK. Dual energy X-ray absorptiometry (DEXA) measurements of bone density and body composition: promise and pitfalls. J Pediatr Endocrinol Metab 2000;13(Suppl 2):983-988.
40. Abramson EC, Chang J, Mayer M, et al. Effects of cisplatin on parathyroid hormone- and human lung tumor-induced bone resorption. J Bone Miner Res 1988;3:541-546.
41. Hoskin PJ, Stratford MR, Folkes LK, et al. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000;355:1428-1429.